Synergistic RNA Delivery Systems for Enhanced Immunization
Legal Citation
Summary of the Inventive Concept
This inventive concept integrates RNA delivery with distinct technologies like AI, IoT, blockchain, and new materials to create more powerful systems for immunization, enhancing immunogenicity and personalized treatment.
Background and Problem Solved
The original patent addressed the need for non-viral delivery of RNA for immunization, but it had limitations in terms of optimizing RNA sequences, monitoring immune responses, and ensuring the integrity of RNA replicons. This new concept solves these problems by synergistically combining RNA delivery with AI, IoT, blockchain, and new materials to create more effective and personalized immunization systems.
Detailed Description of the Inventive Concept
The inventive concept comprises a range of systems and methods that integrate RNA delivery with AI-powered RNA sequence optimization, IoT-enabled real-time immune response monitoring, blockchain-secured RNA replicons, and nanomaterial-based RNA carriers. For instance, one embodiment involves a liposome-based delivery vehicle integrated with an AI-powered RNA sequence optimization module to enhance immunogenicity. Another embodiment features a composition for RNA-based immunization that comprises a blockchain-secured RNA replicon encoding a protein of interest and a microRNA-based adjuvant for enhanced immune activation. These systems and methods can be tailored to specific diseases and patient populations, enabling personalized immunotherapy.
Novelty and Inventive Step
The new claims introduce a synergistic combination of RNA delivery with distinct technologies, which is not obvious from the original patent. The integration of AI, IoT, blockchain, and new materials with RNA delivery creates a new, more powerful system that enhances immunogenicity and personalized treatment, which is not anticipated by the original patent.
Alternative Embodiments and Variations
Alternative embodiments may include the use of different AI algorithms for RNA sequence optimization, various IoT sensors for real-time immune response monitoring, or alternative blockchain protocols for securing RNA replicons. Other variations may involve the use of different nanomaterials for RNA carriers or the integration of additional technologies like CRISPR-Cas9 gene editing.
Potential Commercial Applications and Market
This inventive concept has significant commercial potential in the fields of immunotherapy, vaccine development, and personalized medicine. The target market includes pharmaceutical companies, biotech firms, and research institutions focused on developing innovative immunization systems.
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Molecular biology and immunology, specifically non-viral RNA delivery systems for immunization, requiring expertise in molecular engineering, immunology, and advanced drug delivery technologies
Person of Ordinary Skill (PHOSITA) Profile
A researcher with advanced degrees in molecular biology or bioengineering, familiar with RNA modification techniques, drug delivery systems, and emerging technologies in immunization strategies
Obviousness Rationale
A PHOSITA would recognize that integrating emerging technologies like AI, IoT, and blockchain with existing RNA delivery methods represents a predictable extension of known RNA delivery principles. The core RNA delivery mechanism remains fundamentally consistent with the source patent, with technological augmentations that are well-understood in the field of advanced immunization strategies. The proposed variations represent logical combinations of known techniques to enhance existing RNA delivery approaches.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,562 |
|---|---|
| Title | Delivery of RNA to trigger multiple immune pathways |
| Assignee(s) | GlaxoSmith Kline Biologicals S.A. |